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A sarcoma is a rare kind of cancer (incidence estimated in Europe at 4 to 6 / 100,000) developing from connective tissue and classified as an orphan disease. These tumors of the supporting tissues affect soft tissues (≈ 60%), viscera (≈ 30%) and bones (≈ 10%) [1] . The incidence of soft tissue and visceral sarcomas is around 4,000 new cases per year. Sarcomas are highly heterogeneous with more than 50 subtypes. This great diversity can cause diagnostic confusion and lead to delayed or inappropriate management. 1: Ducimetière F, Lurkin A, Ranchère-Vince D, et al. Incidence of Sarcoma Histotypes and molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing. Najbauer J, ed. PLoS ONE. 2011; 6(8) :e20294.
Expert networks
As requested by action 23.1 of the Cancer plan, the French National Cancer Institute (INCa) has set up networks of anatomopathological and clinical expert centers for rare cancers. For soft tissue sarcomas (STS), the reference network for soft tissue and visceral sarcoma pathology (RRePS) and the soft tissue and visceral sarcoma clinical reference network (NetSarc) were created in 2010. These networks are respectively responsible for confirming diagnoses through systematic double reading of tumor specimens and optimizing patient management thanks to multidisciplinary consultative meetings (RCP). They participate in the epidemiological surveillance and observation of STS and created for this purpose 2 additional national databases (ongoing convergence 
Comment
The databases are interfaced to allow for comprehensive patient monitoring Mainly French patients included
Background Objectives
Primary objective: To describe how patients with advanced STS are managed in France. Secondary objectives: -To describe the epidemiological characteristics of patients with sarcoma and patients with STS -To describe the diagnostic procedures and therapeutic strategy to manage patients with STS.
* LA = Locally advanced * CT = Chemotherapy The European database currently contains data from 12,485 patients registered by the French Sarcoma Group centers with 9,736 soft tissues and visceral sarcomas. Data from patients, aged 18 and over, who were diagnosed with STS in 2012 and 2013, will be extracted from the Conticabase database. Part of these data will be linked or matched with the shared database from the French networks RRePS and NetSarc, with the prior consent of the member expert centers. The extraction and analysis of data will be performed by the French Sarcoma Group (GSF). Results are expected in December 2015. The study period was chosen to reflect the current situation in terms of diagnosis and management in France.
Inclusion and exclusion criteria
An estimated 70% of patients diagnosed with STS in 2013 have been followed up by a reference center and that more of 90% benefited from a double reading by the RRePS network [2, 3] . These patients will therefore be included in the NetSarc and RRePS databases. The overall data collected via these expert networks and compiled in the "Sarcoma clinicobiological database" will ensure a good representativeness of STS at national level. The study period was defined to reflect the current situation in terms of diagnosis and management in France, within a structured territorial network of expert centers. Review and outlook 3:https://rreps.sarcomabcb.org/report/chartReport.htm?name=chartReportNumberOfCasesByRegion This pharmacoepidemiologic study shows the interest of building up medical databases and linking them to study rare diseases and their management in real life. By providing recent and high-quality epidemiological data on STS, this study will meet the need for describing a condition for which classic epidemiology is limited by the disease rarity and extreme heterogeneity. This study is carried out as part of a public/private partnership. Thanks to the data it will generate, it may indirectly support the market access of innovative molecules, provided they are registered by Health Authorities, in the current treatment armamentarium for STS which is still very limited.
2: INCa 2015 report: French national networks for rare cancers in adults /
This study was funded by Merck KGaA. Darmstadt, Germany. For this study no sample size calculations are required. Descriptive statistics will be applied, based on the number of patients identified in the databases. 
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